


APPLICATION

Clarithromycin and Related Substances Ph. Eur. monograph 1651

Overview

The Ph. Eur. Monograph 1651 outlines the separation of Clarithromycin from impurities. This method was studied and improvements were made to provide faster separations within allowable adjustments.



Ph. Eur. Monograph 1651 Details


Reference Solution	(d) Dissolve 15 mg of Clarithromycin for peak identification CRS* in 5 mL of acetonitrile and dilute to 10 mL with water		
Column			
Size	100 x 4.6 mm		
Stationary Phase	Octadecylsilyl silica gel for chromatography R (3.5 µm)		
Temperature	40°C		
Mobile Phase	A: 4.76 g/L solution of potassium dihydrogen phosphate adjusted to pH 4.4 with dilute phosphoric acid B: Acetonitrile		
Gradient	Time (min) %B 0 - 32 min 25 → 60 32- 34 min 60		
Flow Rate	1.1 mL/min		
Detection	Spectrophotometer @ 205 nm		
Injection	10µL		
Relative Retention with Re	ference to Clarithromycin (about 11 min)**		
Impurity A	about 0.42		
Impurity J	about 0.63		
Impurity L	about 0.74		
Impurity B	about 0.79		
Impurity M	about 0.81		
Impurity C	about 0.89		
Impurity D	about 0.96		
Impurity N	about 1.15		
Impurity E	about 1.27		
Impurity F	about 1.33		
Impurity P	about 1.35		
Impurity O	about 1.41		
Impurity K	about 1.59		
Impurity G	about 1.59		
Impurity H	about 1.82		
System Suitability			
Peak-to-Valley Ratio	Minimum 3.0, where Hp = height above the baseline of the peak due to Impurity D and Hv = height above the baseline of		

Minimum 3.0, where Hp = height above the bas ine of the peak due to Impurity D and Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to Clarithromycin in the chromatogram obtained with reference solution D

* Ph. Eur. Standard Clarithromycin for peak identification CRS Y0000321 was purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) - Council of Europe; Postal address: 7 Allée Kastner CS 30026F - 67081 STRASBOURG (France).

** Retention times, relative retentions, and retardation factors are provided for information only and are not mandatory, no deviation allowance is defined.







Adjustments for Meeting System Suitability

(European Pharmacopeia 9.0, Chapter 2.2.46. Chromatographic separation techniques)

Method Parameter	Allowed Adjustments (isocratic elution)	Method 1
Mobile Phase pH	± 0.2 units	As specified
Concentration of Salts in Buffer	± 10 %	As specified in Monograph 1651 Details Table
Composition of the Mobile Phase	\pm 30 % of the minor solvent component relative or 2 % absolute, whichever is the larger. No other component is altered by more than 10 % absolute.	As specified in Monograph 1651 Details Table
Wavelength of Detector	No deviations permitted	205nm (as specified)
Injection Volume	May be decreased, provided detection and repeatability of the peak(s) to be determined are satisfactory.	1 µL (as specified)
Column Temperature	± 10°C	40 °C (as specified)
Stationary Phase	No change of the identity of the substituent permitted (e.g. no replacement of C18 by C8)	Octadecylsilyl silica gel for chromatography (as specified)
Column Length	± 70 %	100mm (as specified)
Column Internal Diameter	± 25 %	4.6 mm (as specified)
Particle Size	-50 %	3.5 µm (as specified)
Flow Rate	± 50 %	1.1 mL/min (as specified)

Kinetex® Ordering Information

3.5 µm Analytical Columns (mm)			SecurityGuard ULTRA Cartridges [‡]
Phases	100 x 4.6	150 x 4.6	3/pk
XB-C18	00D-4744-E0	00F-4744-E0	AJ0-8768
			for 4.6 mm ID



If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to a competing product of the same particle size, similiar phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.



PLICATIC

Australia

t: +61 (0)2-9428-6444 f: +61 (0)2-9428-6445 auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301 f: +43 (0)1-319-1300 anfrage@phenomenex.com

Belaium

t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) f: +31 (0)30-2383749 beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681 f: +1 (310) 328-7768 info@phenomenex.com

China

t: +86 400-606-8099 f: +86 (0)22 2532-1033 phen@agela.com

Denmark

t: +45 4824 8048 f: +45 4810 6265 nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063 f: +45 4810 6265 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 f: +33 (0)1 30 09 21 11 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 f: +49 (0)6021-58830-11 anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400 f: +91 (0)40-3012 2411 indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405 f: +44 1625-501796 eireinfo@phenomenex.com

Italy t: +39 051 6327511

f: +39 051 6327555 italiainfo@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com

Luxembourg

t: +31 (0)30-2418700 f: +31 (0)30-2383749

nlinfo@phenomenex.com

Mexico t: 01-800-844-5226

f: 001-310-328-7768 tecnicomx@phenomenex.com

The Netherlands

- t: +31 (0)30-2418700 f: +31 (0)30-2383749
- nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951 f: +64 (0)9-4780952 nzinfo@phenomenex.com

- **Norway** t: +47 810 02 005
- f: +45 4810 6265 nordicinfo@phenomenex.com

Puerto Rico

- t: +1 (800) 541-HPLC
- f: +1 (310) 328-7768 info@phenomenex.com

Spain

t: +34 91-413-8613 f: +34 91-413-2290 espinfo@phenomenex.com

Sweden

- t: +46 (0)8 611 6950
- f: +45 4810 6265 nordicinfo@phenomenex.com

United Kingdom

- t: +44 (0)1625-501367 f: +44 (0)1625-501796
- ukinfo@phenomenex.com

USA

- t: +1 (310) 212-0555 f: +1 (310) 328-7768
- info@phenomenex.com
- All other countries Corporate Office USA
- f: +1 (310) 328-7768
- info@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Kinetex is a registered trademark and. MidBore, and SecurityGuard are trademarks of Phenomenex

© 2017 Phenomenex, Inc. All rights reserved.